

# UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

November 3, 2003

Date of Deposit

Janice M. Minner

Signature

EL 964823004 US

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: **DEAV2002/0070 US NP**  
INVENTORS: **KLINGER, et al.**  
TITLE: **NOVEL PYRIMIDINE-4,6-DICARBOXYLIC ACID DIAMIDES FOR SELECTIVELY INHIBITING COLLAGENASES**

## APPLICATION ELEMENTS

|  |   |              |                                  |
|--|---|--------------|----------------------------------|
| 1. <input checked="" type="checkbox"/> | *Fee Transmittal Form (e.g., PTO/SB/17)<br><i>(Submit an original and a duplicate for fee processing)</i>   | Total Pages  | <input type="text" value="112"/> |
| 2. <input checked="" type="checkbox"/> | Specification<br><i>(preferred arrangement set forth below)</i>   | Total Pages  | <input type="text" value="112"/> |
|  | - Descriptive title of the Invention<br>- Cross References to Related Applications<br>- Statement Regarding Fed sponsored R & D<br>- Reference to Microfiche Appendix<br>- Background of the Invention<br>- Brief Summary of the Invention<br>- Brief Description of the Drawings <i>(if filed)</i><br>- Detailed Description<br>- Claim(s)<br>- Abstract of the Disclosure |              |                                  |
| 3. <input type="checkbox"/>            | Drawing(s) (35 U.S.C. 113)  | Total Sheets | <input type="text"/>             |
| 4. <input type="checkbox"/>            | Oath or Declaration   | Total Pages  | <input type="text" value="2"/>   |
| a. <input checked="" type="checkbox"/> | Newly unexecuted (original or copy)   |              |                                  |
| b. <input type="checkbox"/>            | Copy from a prior application (37 CFR § 1.63(d))  |              |                                  |
| i. <input type="checkbox"/>            | <u>DELETION OF INVENTOR(S)</u><br>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).  |              |                                  |
| 5. <input type="checkbox"/>            | Nucleotide and/or Amino Acid Sequence Submission<br><i>(if applicable, all necessary)</i>   |              |                                  |
| a. <input type="checkbox"/>            | Computer Readable Copy  |              |                                  |
| b. <input type="checkbox"/>            | Paper Copy (identical to computer copy)   |              |                                  |
| c. <input type="checkbox"/>            | Statement verifying identity of above copies  |              |                                  |

17548 U.S.PTO  
10/700273  
110303



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT**

(\$ 770.00)

**C mplete if Known**

|                      |                     |
|----------------------|---------------------|
| Application Number   | Not Yet Assigned    |
| Filing Date          | November 3, 2003    |
| First Named Inventor | KLINGLER, et al.    |
| Examiner Name        | Not Yet Assigned    |
| Group / Art Unit     | Not Yet Assigned    |
| Attorney Docket No.  | DEAV2002/0070 US NP |

**METHOD OF PAYMENT (check all that apply)**
 Check  Credit Card  Money  Other  None  
 Deposit Account

Deposit Account Number

18-1982

Deposit Account Name

Aventis Pharmaceuticals Inc.

The Commissioner is authorized to: (check all that apply)

 Charge fee(s) indicated below  Credit any overpayments  
 Charge any additional fee(s) during the pendency of this application  
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account
**FEE CALCULATION****1. BASIC FILING FEE**

| Large Entity        | Small Entity | Fee Description        | Fee Paid |
|---------------------|--------------|------------------------|----------|
| Fee Code            | Fee Code     |                        |          |
| 1001 770            | 2001 375     | Utility filing fee     | 770      |
| 1002 340            | 2002 165     | Design filing Fee      |          |
| 1003 530            | 2003 260     | Plant filing fee       |          |
| 1004 770            | 2004 375     | Reissue filing fee     |          |
| 1005 160            | 2005 80      | Provisional filing fee |          |
| <b>SUBTOTAL (1)</b> |              | <b>(\$770.00)</b>      |          |

**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

|                    | Extra Claims | Fee from below | Fee Paid |
|--------------------|--------------|----------------|----------|
| Total Claims       | 12           | -20**= 0       | x 0 = 0  |
| Independent Claims | 1            | - 3**= 0       | x 0 = 0  |
| Multiple Dependent |              | 0              | = 0      |

| Large Entity        | Small Entity | Fee Description   |
|---------------------|--------------|---|
| Fee Code            | Fee Code     |   |
| 1202 18             | 2202 9       | Claims in excess of 20                                    |
| 1201 86             | 2201 42      | Independent claims in excess of 3                         |
| 1203 290            | 2203 140     | Multiple dependent claim, if not paid                     |
| 1204 86             | 2204 42      | **Reissue independent claims over original patent         |
| 1205 18             | 2205 9       | **Reissue claims in excess of 20 and over original patent |
| <b>SUBTOTAL (2)</b> |              | <b>(\$0.00)</b>   |


\*\*or number previously paid, if greater; For Reissues, see above

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

| Large Entity        | Small Entity | Fee Description | Fee Paid   |
|---------------------|--------------|-----------------|--|
| Fee Code            | Fee (\$)     | Fee Code        | Fee (\$)   |
| 1051 130            |              | 2051 65         | Surcharge - late filing fee or oath  |
| 1052 50             |              | 2052 25         | Surcharge - late provisional filing fee or cover sheet                     |
| 1053 130            |              | 1053 130        | Non-English Specification  |
| 1812 2,520          |              | 1812 2,520      | For filing a request for reexamination                                     |
| 1804 920*           |              | 1804 920*       | Requesting publication of SIR prior to Examiner action                     |
| 1805 1,840*         |              | 1805 1,840*     | Requesting publication of SIR after Examiner action                        |
| 1251 110            |              | 2251 55         | Extension for reply within first month                                     |
| 1252 420            |              | 2252 205        | Extension for reply within second month                                    |
| 1253 950            |              | 2253 465        | Extension for reply within third month                                     |
| 1254 1,480          |              | 2254 725        | Extension for reply within fourth month                                    |
| 1255 2,010          |              | 2255 985        | Extension for reply within fifth month                                     |
| 1401 330            |              | 2401 160        | Notice of Appeal   |
| 1402 330            |              | 2402 160        | Filing a brief in support of an appeal                                     |
| 1403 290            |              | 2403 140        | Request for oral hearing   |
| 1451 1,510          |              | 1451 1,510      | Petition to institute a public use proceeding                              |
| 1452 110            |              | 2452 55         | Petition to revive - unavoidable   |
| 1453 1,330          |              | 2453 650        | Petition to revive - unintentional   |
| 1501 1,330          |              | 2501 650        | Utility issue fee (or reissue)   |
| 1502 480            |              | 2502 235        | Design issue fee   |
| 1503 640            |              | 2503 315        | Plant issue fee  |
| 1460 130            |              | 1460 130        | Petitions to the Commissioner  |
| 1807 50             |              | 1807 50         | Petitions related to provisional applications                              |
| 1806 180            |              | 1806 180        | Submission of Information Disclosure Stmt                                  |
| 8021 40             |              | 8021 40         | Recording each patent assignment per property (times number of properties) |
| 1809 770            |              | 2809 375        | Filing a submission after final rejection (37 CFR § 1.129(a))              |
| 1810 770            |              | 2810 375        | For each additional invention to be examined (37 CFR § 1.129(b))           |
| 1801 770            |              | 2801 375        | Request for Continued Examination (RCE)                                    |
| 1802 900            |              | 1802 900        | Request for expedited examination of a design application                  |
| Other fee (specify) |              |                 |  |

\*Reduced by Basic Filing Fee Paid

**SUBTOTAL (3)** (\$)**SUBMITTED BY****Complete (If applicable)**

|                   |   |                                   |        |           |                  |
|-------------------|---|-----------------------------------|--------|-----------|------------------|
| Name (Print/Type) | Julie Anne Knight, Reg. No. 48,867  | Registration No. (Attorney/Agent) | 48,867 | Telephone | (908) 231-3679   |
| Signature         |  |                                   |        | Date      | November 3, 2003 |

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template

If a **CONTINUING Application**, check appropriate box, and supply the requisite information:

Continuation     Divisional     Continuation-in-part

of prior application no: \_\_\_\_\_, filed \_\_\_\_\_

Examiner \_\_\_\_\_, Group/Art Unit \_\_\_\_\_

(The cross reference has been/will be inserted on page one of the specification).

This application claims the benefit of U.S. Provisional Application No. 60/456,395, filed March 21, 2003 and 60/458,316, filed March 28, 2003.

This application claims the priority to German Application No. 102 51 019.9, filed November 2, 2002 and German Application No. 102 54 092.6, filed November 20, 2002.

**Incorporation By Reference** (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

#### ACCOMPANYING APPLICATION PARTS

6.  Assignment Papers (cover sheet & document(s))
7.  37 CFR §3.73(b) Statement  
(when there is an assignee)
8.  Verified English Translation Document (if applicable)
9.  Information Disclosure  Copies of IDS Citations  
Statement (IDS)/PTO-1449
10.  Preliminary Amendment
11.  Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
12.  \*Small Entity Statement(s)  Statement filed in prior application,  
(PTO/SB/09-12) Status still proper and desired
13.  Certified Copy of Priority Document – DE 102 51 019.9 and DE 102 54 092.6  
(if foreign priority is claimed)
14.  Other: Application Data Sheet

#### CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)



Julie Anne Knight, Reg. No. 48,867  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-3679  
Telefax (908) 231-2626  
Aventis Docket No. DEAV2002/0070 US NP